Possible impact of the standardized Category IV regimen on multidrug-resistant tuberculosis patients in Mumbai

Lung India

Volumn 33, Issue 3, 2016, Pages 253-256

  Udwadia, Zarir ^a   Mullerpattan, Jai ^a   Shah, Kushal ^a   Rodrigues, Camilla ^a  

^a P D HINDUJA NATIONAL HOSPITAL   (India)

Author keywords

Category IV treatment; directly observed treatment short course plus; drug resistant tuberculosis

Indexed keywords

AMIKACIN; CAPREOMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; ISONIAZID PLUS RIFAMPICIN; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; QUINOLONE DERIVATIVE; STREPTOMYCIN;

ARTICLE; DIRECTLY OBSERVED THERAPY; DRUG SENSITIVITY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; INDIA; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANT TUBERCULOSIS; SHORT COURSE THERAPY;

EID: 84968561579     PISSN: 09702113     EISSN: 0974598X     Source Type: Journal    
DOI: 10.4103/0970-2113.180800     Document Type: Article

References (23)

1. Revised National Tuberculosis Programme (RNTCP) - TBC India. Available from: http://www.tbcindia.nic.in/rntcp.html. [Last accessed on 2015 Feb 08]
2. World Health Organization. Global Tuberculosis Report 2013. Geneva, Switzerland: World Health Organization; 2013
3. Revised National Tuberculosis Control Programme. Guidelines for the Programmatic Management of Drug Resistant Tuberculosis (PMDT) in India. New Delhi: Central TB Division; 2012
4. Agrawal D, Udwadia ZF, Rodriguez C, Mehta A. Increasing incidence of fluoroquinolone?resistant Mycobacterium tuberculosis in Mumbai, India. Int J Tuberc Lung Dis 2009;13:79-83
5. World Health Organization. Guidelines for the Programmatic Management of Drug Resistant Tuberculosis: 2011 Update. Geneva, Switzerland: World Health Organization; 2011
6. D'souza DT, Mistry NF, Vira TS, Dholakia Y, Hoffner S, Pasvol G, et al. High levels of multidrug resistant tuberculosis in new and treatment?failure patients from the Revised National Tuberculosis Control Programme in an urban metropolis (Mumbai) in Western India. BMC Public Health 2009;9:211
7. Almeida D, Rodrigues C, Udwadia ZF, Lalvani A, Gothi GD, Mehta P, et al. Incidence of multidrug?resistant tuberculosis in urban and rural India and implications for prevention. Clin Infect Dis 2003;36:e152-4
8. Atre SR, D'Souza DT, Vira TS, Chatterjee A, Mistry NF. Risk factors associated with MDR?TB at the onset of therapy among new cases registered with the RNTCP in Mumbai, India. Indian J Public Health 2011;55:14-21
9. Revised National Tuberculosis Control Programme. TB India 2013. New Delhi: Central TB Division; 2013
10. Mukherjee JS, Rich ML, Socci AR, Joseph JK, Virú FA, Shin SS, et al. Programmes and principles in treatment of multidrug?resistant tuberculosis. Lancet 2004;363:474-81
11. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993;328:527-32
12. Mitnick C, Bayona J, Palacios E, Shin S, Furin J, Alcántara F, et al. Community?based therapy for multidrug?resistant tuberculosis in Lima, Peru. N Engl J Med 2003;348:119-28
13. International Union against Tuberculosis and Lung Disease. Management of Tuberculosis: A Guide for Low Income Countries. 5th ed. Paris: International Union against Tuberculosis and Lung Disease; 2000
14. Portaels F, Rigouts L, Bastian I. Addressing multidrug?resistant tuberculosis in penitentiary hospitals and in the general population of the former Soviet Union. Int J Tuberc Lung Dis 1999;3:582-8
15. Becerra MC, Freeman J, Bayona J, Shin SS, Kim JY, Furin JJ, et al. Using treatment failure under effective directly observed short?course chemotherapy programs to identify patients with multidrug?resistant tuberculosis. Int J Tuberc Lung Dis 2000;4:108-14
16. Caminero JA. Management of multidrug?resistant tuberculosis and patients in retreatment. Eur Respir J 2005;25:928-36
17. Partners in Health, Program in Infectious Disease and Social Change, Harvard Medical School. The PIH Guide to the Medical Management of Multidrug - Resistant Tuberculosis. Boston, MA: Partners in Health; 2003
18. Iseman MD. Treatment of multidrug?resistant tuberculosis. N Engl J Med 1993;329:784-91
19. Caminero JA, March P. Statements of ATS, CDC, and IDSA on treatment of tuberculosis. Am J Respir Crit Care Med 2004;169:316-7
20. Caminero JA,. Guidelines for Clinical and Operational Management of Drug?Resistant Tuberculosis. Paris, France: International Union against Tuberculosis and Lung Disease; 2013
21. Salvo F, Dorjee K, Dierberg K, Cronin W, Sadutshang TD, Migliori GB, et al. Survey of tuberculosis drug resistance among Tibetan refugees in India. Int J Tuberc Lung Dis 2014;18:655-62
22. Zhao Y, Xu S, Wang L, Chin DP, Wang S, Jiang G, et al. National survey of drug?resistant tuberculosis in China. N Engl J Med 2012;366:2161-70
23. Singla R, Sarin R, Khalid UK, Mathuria K, Singla N, Jaiswal A, et al. Seven?year DOTS?plus pilot experience in India: Results, constraints and issues. Int J Tuberc Lung Dis 2009;13:976-81